Tucidinostat
Appearance
![]() | |
Clinical data | |
---|---|
Trade names | Epidaza, Hiyasta |
Other names | Chidamide, HBI-8000 |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C22H19FN4O2 |
Molar mass | 390.418 g·mol−1 |
3D model (JSmol) | |
| |
|
Tucidinostat (INN, also known as chidamide and sold under the brand names Epidaza and Hiyasta) is a histone deacetylase inhibitor (HDI) developed in China.[1] It was also known as HBI-8000.[2] It is a benzamide HDI and inhibits Class I HDAC1, HDAC2, HDAC3, as well as Class IIb HDAC10.[3]
Tucidinostat is approved by the Chinese FDA for relapsed or refractory peripheral T-cell lymphoma (PTCL) and has orphan drug status in Japan.[2][better source needed] In Japan, it was approved for relapsed or refractory adult T-cell leukemia-lymphoma (ATLL) treatment in June 2021.[4]
Tucidinostat is being researched as a treatment for pancreatic cancer.[5][6][7] However, it is not US FDA approved for the treatment of pancreatic cancer.
References
[edit]- ^ Lowe D (April 2015). "China's First Homegrown Pharma". Seeking Alpha.
- ^ a b "Chipscreen Biosciences Announces CFDA Approval of Chidamide (Epidaza) for PTCLs in China" (Press release). PR Newswire Association LLC.
- ^ "HUYA Bioscience International Grants An Exclusive License For HBI-8000 In Japan And Other Asian Countries To Eisai". PR Newswire Association LLC. February 2016.
- ^ "Marketing Approval of HBI-8000 (Tucidinostat) for Relapsed or Refractory ATLL Treatment in Japan" (PDF).
- ^ Qiao Z, Ren S, Li W, Wang X, He M, Guo Y, et al. (April 2013). "Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells". Biochemical and Biophysical Research Communications. 434 (1): 95–101. doi:10.1016/j.bbrc.2013.03.059. PMID 23541946.
- ^ Guha M (April 2015). "HDAC inhibitors still need a home run, despite recent approval". Nature Reviews. Drug Discovery. 14 (4): 225–6. doi:10.1038/nrd4583. PMID 25829268. S2CID 36758974.
- ^ Wang SS (2015-04-02). "A New Cancer Drug, Made in China". The Wall Street Journal. Retrieved 13 April 2015.